Heparin-binding motifs and biofilm formation by candida albicans

Journal of Infectious Diseases

Volumn 208, Issue 10, 2013, Pages 1695-1704

  Green, Julianne V ^a   Orsborn, Kris I ^a   Zhang, Minlu ^c   Tan, Queenie K G ^d   Greis, Kenneth D ^b   Porollo, Alexey ^a   Andes, David R ^e   Lu, Jason Long ^a   Hostetter, Margaret K ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Duke University Medical Center ^*  (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; FUNGAL PROTEIN; HEPARIN; IMMUNOGLOBULIN G; LYSINE; MEMBRANE PROTEIN; PROTEIN ENO1; PROTEIN PGK1; PROTEIN SSA1; PROTEIN SSA2; PROTEIN TDH3; SEPHAROSE; UNCLASSIFIED DRUG; WNT1 PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ARTICLE; BIOFILM; CANDIDA ALBICANS; CENTRAL VENOUS CATHETER; CONTROLLED STUDY; FEMALE; HEPARIN BINDING MOTIF; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; RAT;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; BIOFILMS; CANDIDA ALBICANS; CENTRAL VENOUS CATHETERS; FUNGAL PROTEINS; HEPARIN; MEMBRANE PROTEINS; PROTEIN BINDING; RATS;

EID: 84888591526     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit391     Document Type: Article

References (44)

1. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002; 41:391-412.
2. Hamilton RA, Plis JM, Clay C, Sylvan L. Heparin sodium versus 0.9% sodium chloride injection for maintaining patency of indwelling intermittent infusion devices. Clin Pharm 1988; 7:439-43.
3. Harrop HA, Coombe DR, Rider CC. Heparin specifically inhibits binding of v3 loop antibodies to HIV-1 gp120, an effect potentiated by CD4 binding. AIDS 1994; 8:183-92.
4. Rusnati M, Tulipano G, Spillmann D, et al. Multiple interactions of HIV-1 Tat protein with size-defined heparin oligosaccharides. J Biol Chem 1999; 274:28198-205.
5. Kim S, Wolyniak MJ, Staab JF, Sundstrom P. A 368-base-pair cis-acting HWP1 promoter region, HCR, of Candida albicans confers hyphaspecific gene regulation and binds architectural transcription factors Nhp6 and Gcf1p. Eukaryot Cell 2007; 6:693-709. PMCID: 1865660.
6. Margalit H, Fischer N, Ben-Sasson SA. Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J Biol Chem 1993; 268:19228-31.
7. Torrent M, Nogues MV, Andreu D, Boix E. The "CPCclip motif": A conserved structural signature for heparin-binding proteins. PLoS One 2012; 7:e42692. PMCID: 3412806.
8. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 1989; 9:21-32.
9. Sobel M, Soler DF, Kermode JC, Harris RB. Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 1992; 267:8857-62.
10. Farshi P, Ohlig S, Pickhinke U, et al. Dual roles of the Cardin- Weintraub motif in multimeric Sonic Hedgehog. J Biol Chem 2011; 286:23608-19. PMCID: 3123124.
11. Chaffin WL. Candida albicans cell wall proteins. Microbiol Mol Biol Rev 2008; 72:495-544. PMCID: 2546859.
12. Alberti-Segui C, Morales AJ, Xing H, et al. Identification of potential cell-surface proteins in Candida albicans and investigation of the role of a putative cell-surface glycosidase in adhesion and virulence. Yeast 2004; 21:285-302.
13. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: Signalp 3.0. J Mol Biol 2004; 340:783-95.
14. Fankhauser N, Maser P. Identification of GPI anchor attachment signals by a kohonen self-organizing map. Bioinformatics 2005; 21:1846-52.
15. Pierleoni A, Martelli PL, Casadio R. Predgpi: A GPI-anchor predictor. BMC Bioinformatics 2008; 9:392. PMCID: 2571997.
16. Mao Y, Zhang Z, Gast C, Wong B. C-terminal signals regulate targeting of glycosylphosphatidylinositol-anchored proteins to the cell wall or plasma membrane in Candida albicans. Eukaryot Cell 2008; 7:1906-15. PMCID: 2583546.
17. Wilson RB, Davis D, Mitchell AP. Rapid hypothesis testing with Candida albicans through gene disruption with short homology regions. J Bacteriol 1999; 181:1868-74.
18. Osmond RI, Kett WC, Skett SE, Coombe DR. Protein-heparin interactions measured by Biacore 2000 are affected by the method of heparin immobilization. Anal Biochem 2002; 310:199-207.
19. Marson A, Robinson DE, Brookes PN, et al. Development of a microtiter plate-based glycosaminoglycan array for the investigation of glycosaminoglycan-protein interactions. Glycobiology 2009; 19: 1537-46.
20. Hoffman CS, Winston F. A ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene 1987; 57:267-72.
21. Sambrook J, Fritsch FE, Maniatis T. Molecular cloning: A laboratory manual. 2nd ed. New York, NY: Cold Spring Harbor Laboratory Press, 1989.
22. Devore-Carter D, Kar S, Vellucci V, Bhattacherjee V, Domanski P, Hostetter MK. Superantigen-like effects of a Candida albicans polypeptide. J Infect Dis 2008; 197:981-9.
23. Cormack B. 2001 Directed Mutagenesis Using the Polymerase Chain Reaction. Current Protocols in Molecular Biology. 37:8.5.1-8.5.10.
24. Eismann T, Huber N, Shin T, et al. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am J Physiol Gastrointest Liver Physiol 2009; 296:G266-74. PMCID: 2643922.
25. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 2004; 72:6023-31. PMCID: 517581.
26. Nobile CJ, Fox EP, Nett JE, et al. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 2012; 148:126-38. PMCID: 3266547.
27. Raman R, Sasisekharan V, Sasisekharan R. Structural insights into biological roles of protein-glycosaminoglycan interactions. Chem Biol 2005; 12:267-77.
28. Gale CA, Bendel CM, McClellan M, et al. Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science 1998; 279:1355-8.
29. Mochon AB, Jin Y, Kayala MA, et al. Serological profiling of a Candida albicans protein microarray reveals permanent host-pathogen interplay and stage-specific responses during candidemia. PLoS Pathogens 2010; 6:e1000827. PMCID: 2845659.
30. Xiao K, Shenoy SK, Nobles K, Lefkowitz RJ. Activation-dependent conformational changes in β-arrestin 2. J Biol Chem 2004; 279: 55744-53.
31. Lortat-Jacob H, Grimaud JA. Interferon-gamma c-terminal function: new working hypothesis-heparan sulfate and heparin, new targets for IFN-gamma, protect, relax the cytokine and regulate its activity. Cell Mol Biol 1991; 37:253-60.
32. Sundstrom P, Aliaga GR. Molecular cloning of cDNA and analysis of protein secondary structure of Candida albicans enolase, an abundant, immunodominant glycolytic enzyme. J Bacteriol 1992; 174:6789-99. PMCID: 207354.
33. Pitarch A, Diez-Orejas R, Molero G, et al. Analysis of the serologic response to systemic Candida albicans infection in a murine model. Proteomics 2001; 1:550-9.
34. Pitarch A, Abian J, Carrascal M, Sanchez M, Nombela C, Gil C. Proteomics- based identification of novel Candida albicans antigens for diagnosis of systemic candidiasis in patients with underlying hematological malignancies. Proteomics 2004; 4:3084-106.
35. Li XS, Reddy MS, Baev D, Edgerton M. Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5. J Biol Chem 2003; 278:28553-61.
36. Nobile CJ, Mitchell AP. Genetics and genomics of Candida albicans biofilm formation. Cell Microbiol 2006; 8:1382-91.
37. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence 2013; 4:119-28.
38. Miceli MH, Bernardo SM, Ku TS, Walraven C, Lee SA. In vitro analyses of the effects of heparin and parabens on Candida albicans biofilms and planktonic cells. Antimicrob Agents Chemother 2012; 56:148-53. PMCID: 3256088.
39. Nobile CJ, Andes DR, Nett JE, et al. Critical role of BCR1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathogens 2006; 2:e63.
40. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1-45.
41. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990: national nosocomial infections surveillance system. J Infect Dis 1993; 167:1247-51.
42. Carrasco MN, Bueno A, de las Cuevas C, et al. Evaluation of a triplelumen central venous heparin-coated catheter versus a catheter coated with chlorhexidine and silver sulfadiazine in critically ill patients. Intensive Care Med 2004; 30:633-8.
43. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Is systemic heparin a risk factor for catheter-related sepsis in dialysis patients? an evaluation of various biofilm and traditional risk factors. Nephron Clinical Practice 2007; 107:c128-32.
44. Shanks RM, Donegan NP, Graber ML, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005; 73: 4596-606.